

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6690651

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	COVIDIEN LP	02/17/2021
RECEIVING PARTY DATA		
Name:	COVIDIEN AG	
Street Address:	VICTOR VON BRUNS-STRASSE 19	
City:	NEUHAUSEN AM RHEINFALL, SCHAFFHAUSEN	
State/Country:	SWITZERLAND	
Postal Code:	8212	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16091054
CORRESPONDENCE DATA		
Fax Number:	(651)735-1102	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6517351100	
Email:	pairdocketing@ssiplaw.com	
Correspondent Name:	SHUMAKER & SIEFFERT, P.A.	
Address Line 1:	1625 RADIO DRIVE, SUITE 100	
Address Line 4:	WOODBURY, MINNESOTA 55125	
ATTORNEY DOCKET NUMBER:	1216-109US01	
NAME OF SUBMITTER:	JENNIFER DALLMAN	
SIGNATURE:	/JENNIFER DALLMAN/	
DATE SIGNED:	05/04/2021	
Total Attachments: 5		
source=A0004067US02_CovidienLPtoAG#page1.tif		
source=A0004067US02_CovidienLPtoAG#page2.tif		
source=A0004067US02_CovidienLPtoAG#page3.tif		
source=A0004067US02_CovidienLPtoAG#page4.tif		
source=A0004067US02_CovidienLPtoAG#page5.tif		

ASSIGNMENT

This Assignment is made by and between Covidien LP, a limited partnership organized and existing under the laws of the State of Delaware, having a place of business at 15 Hampshire Street, Mansfield, MA 02048 (the "Assignor") and Covidien AG, a company organized under the laws of Switzerland, having a place of business at Victor von Bruns-Strasse 19, Neuhausen am Rheinfall, Schaffhausen, 8212 Switzerland (the "Assignee").

WHEREAS, Assignor and Assignee are wholly owned members of the Medtronic PLC group of companies.

WHEREAS, Assignor is an owner of inventions for which the following patent applications have been filed and patents have been granted:

U.S. Provisional Application no. 62/948,506, filed December 16, 2019, entitled, "ALGORITHMS FOR THE ANALYSIS OF TRANSMISSION LASER SPECKLE IMAGING INFORMATION";

U.S. Provisional Application no. 62/596,761, filed December 8, 2017, entitled, "METHOD FOR ASSESSING VASCULAR FUNCTION USING LASER SPECKLE IMAGING IN A TRANSMISSION GEOMETRY DURING REACTIVE HYPEREMIA";

U.S. Provisional Application no. 62/324,903, filed April 20, 2016, entitled, "CALIBRATED SPECKLE CONTRAST FLOWMETER";

U.S. Provisional Application no. 62/318,884, filed April 6, 2016, entitled, "SYSTEM FOR BLOOD FLOW MEASUREMENT WITH AFFIXED LASER SPECKLE CONTRAST ANALYSIS";

International Patent Application no. PCT/US2017/028178, filed April 18, 2017, entitled, "SYSTEMS AND METHODS FOR CALIBRATING AND CORRECTING A SPECKLE CONTRAST FLOWMETER," and the following related national phase applications:

Canadian Patent Application no. 3018621, filed September 20, 2018,

Chinese Patent Application no. 201780024284.X, filed October 18, 2018,

European Patent Application no. 17786485.7, filed September 20, 2018, and

U.S. Patent Application no. 16/093,597, filed October 12, 2018;
International Patent Application no. PCT/US2017/025979, filed April 4, 2017, entitled,
“SYSTEM FOR BLOOD FLOW MEASUREMENT WITH AFFIXED LASER SPECKLE
CONTRAST ANALYSIS,” and the following related national phase applications:

Canadian Patent Application no. 3018567, filed September 20, 2018,
Chinese Patent Application no. 201780029605.5, filed November 13, 2018,
European Patent Application no. 17779676.0, filed September 19, 2018, and
U.S. Patent Application no. 16/091,054, filed October 3, 2018;

U.S. Patent Application no. 15/488,263, filed April 14, 2017, entitled, “NON-INVASIVE
HEMODYNAMIC ASSESSMENT VIA INTERROGATION OF BIOLOGICAL TISSUE
USING A COHERENT LIGHT SOURCE”;

International Patent Application no. PCT/US2018/27769, filed April 16, 2018, entitled,
“NON-INVASIVE HEMODYNAMIC ASSESSMENT VIA INTERROGATION OF
BIOLOGICAL TISSUE USING A COHERENT LIGHT SOURCE,” and the following related
national phase applications:

Canadian Patent Application no. 3059804, filed October 10, 2019,
Chinese Patent Application no. 2018800388564, filed December 11, 2019, and
European Patent Application no. 18784914.6, filed November 13, 2019;

U.S. Patent Application no. 15/850,391, filed December 21, 2017, entitled “PERFUSION
ASSESSMENT USING TRANSMISSION LASER SPECKLE IMAGING;”

U.S. Patent no. 9,848,787, issued December 26, 2017, entitled “PERFUSION
ASSESSMENT USING TRANSMISSION LASER SPECKLE IMAGING;” and

U.S. Patent Application no. 17/091,803, filed November 6, 2020, entitled,
“ALGORITHMS FOR THE ANALYSIS OF TRANSMISSION LASER SPECKLE IMAGING
INFORMATION.”

WHEREAS, Assignor is an owner of the trademark “FLOWMET” registered on October 22,
2019 as Registration no. 5889436, the application for which was filed on March 15, 2019 with
Serial no. 88-342522.

WHEREAS, Assignee desires to acquire Assignor's entire right, title and interest throughout the world in and to the trademarks and inventions, including the entire right, title and interest in and to the above-identified U.S. provisional applications and all other U.S. and foreign applications filed for the inventions and in and to all U.S. or foreign patents granted for the inventions, and including any and all rights of priority in the inventions, including any and all rights of priority in the above-identified U.S. provisional applications and all other U.S. and foreign applications filed for the inventions.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and in view of the Assignor and Assignee being members of the Medtronic PLC group of companies, Assignor has sold, assigned, conveyed and transferred and hereby does sell, assign, convey and transfer to Assignee, and its successors, legal representatives, and assigns, Assignor's entire right, title and interest throughout the world in and to the trademarks and inventions, including the entire right, title and interest in and to all applications that have been filed or may be filed for the inventions in the U.S. or in any foreign country, countries or organizations, including the above-identified U.S. provisional applications, U.S. patent applications, and International patent applications, any provisional applications to which they claim priority and all U.S. or foreign applications claiming benefit or priority to the above-identified U.S. provisional applications, and including any other provisional applications, non-provisional applications, continuation applications, continuation-in-part applications, divisional applications, reissue applications, reexamination applications, renewal applications, extension applications, or design applications for any of the inventions, and in and to all U.S. patents, foreign patents, utility models, design registrations, inventor's certificates and other like rights of exclusion granted for the inventions, including all patents granted on or based on the above-identified U.S. provisional applications, U.S. patent applications, and International patent applications, or any of the other foregoing applications in the U.S. or any foreign country, countries, or organizations, and further including all rights of priority in the inventions and in the above-identified U.S. provisional applications, U.S. patent applications, and International patent applications and any of the other foregoing applications under international conventions, treaties, laws or agreements, including the right to file the above-identified U.S. provisional applications, U.S. patent applications, and International patent applications and any of the other foregoing

applications and the right to claim the priority of the above-identified U.S. provisional applications, U.S. patent applications, and International patent applications and any of the other foregoing applications under the International Convention for the Protection of Industrial Property, or any other conventions, treaties, laws or agreements of like purposes, to be held and enjoyed by Assignee and its successors, legal representatives, and assigns, for its own use and benefit and use and benefit of its successors, legal representatives, and assigns, to the full end of the term for which any of the U.S. patents, foreign patents, utility models, design registrations, inventor's certificates or other rights of exclusion are granted.

AND, Assignor does hereby authorize and request the Commissioner of Patents of the U.S., and any official of any country, countries or organizations foreign to the U.S., having an applicable duty, to issue all trademarks, patents, utility models, design registrations, inventor's certificates and other like rights of exclusion granted for the inventions to the Assignee, its successors, legal representatives, and assigns as the assignee of the entire, right, title and interest therein.

AND, Assignor does hereby authorize the Assignee to apply in all countries in Assignor's name or in Assignee's name for trademarks, U.S. patents, foreign patents, utility models, design registrations, inventor's certificates and like rights of exclusion for the inventions, and Assignor agrees for itself and its respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this Assignment.

The parties agree that this Assignment shall be governed under the laws of the United States.

The parties, intending to be legally bound, through their duly authorized representatives have executed this Assignment.

Date: 2/17/2021



On behalf of **Covidien LP (Assignor)**
Philip J. Albert
Vice President

Date: Feb 8, 2021



On behalf of **Covidien AG (Assignee)**
Hakan Olsson
Director

Covidien AG
Victor von Bruns-Strasse 19
8212 Neuhausen am Rheinfall
Switzerland
Phone + 41 (0)52 556 0600